Covaxin interim efficacy very good, awaiting more data and full results: Dr Gagandeep Kang
These countries are highly satisfied with the safe, inactivated vaccine technology and robust data package for safety and immunogenicity.” The much-awaited result from the phase 3 clinical trials of Covaxin, the vaccine that has been granted emergency use authorization under a trial mode, is finally out and the news seems encouraging. What is however awaited … Read more